Keros Therapeutics, Inc. (KROS) vs Protalix BioTherapeutics, Inc. (PLX)

Keros Therapeutics, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($229.0M and $221.6M). Keros Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.3×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against −84.6%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs −1,345.3%). Across the 18 metrics below, Protalix BioTherapeutics, Inc. leads on 10 and Keros Therapeutics, Inc. on 8.